Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer
To assess the frequency and prognostic impact of Ep‐CAM and Her‐2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow‐up of 10.8 years were enrolled in this retrospective study. Overexpress...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 2002-04, Vol.98 (6), p.883-888 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 888 |
|---|---|
| container_issue | 6 |
| container_start_page | 883 |
| container_title | International journal of cancer |
| container_volume | 98 |
| creator | Spizzo, Gilbert Obrist, Peter Ensinger, Christian Theurl, Igor Dünser, Martina Ramoni, Angela Gunsilius, Eberhard Eibl, Günther Mikuz, Gregor Gastl, Günther |
| description | To assess the frequency and prognostic impact of Ep‐CAM and Her‐2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow‐up of 10.8 years were enrolled in this retrospective study. Overexpression of Ep‐CAM and Her‐2/neu in tumor tissue samples was assessed by immunohistochemistry. Tumors presenting a Her‐2/neu 2+ staining were additionally analyzed by FISH to exclude false positive results. Ep‐CAM and Her‐2/neu overexpression was found in 35.6% and 19.5% of the tumor samples, respectively. Both Ep‐CAM and Her‐2/neu overexpression were predictive for poor disease‐free (DFS) and disease‐related overall survival (DROS). Concurrent Ep‐CAM and Her‐2/neu overexpression was present in 13.2% of tumor specimens and had an additive negative impact on DFS and DROS. This minority of patients had a median time to relapse of only 34 months, whereas the median time to relapse was not reached in the patient population without Her‐2/neu and Ep‐CAM overexpression. By multivariate analysis Ep‐CAM overexpression proved to be an indicator of poor prognosis, independent of tumor size, histologic grade, hormone receptor expression and Her‐2/neu overexpression. In conclusion, overexpression of Ep‐CAM and Her‐2/neu complement each other as predictors for poor prognosis in patients with invasive breast cancer. Determination of these tumor markers should help in assigning breast cancer patients to 1 of 3 distinct risk categories. © 2002 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/ijc.10270 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71591515</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71591515</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4830-d5f59b92e8e8afb81ff221bc20e9c876e8f39210afe28f79cf1079b401e9f2b33</originalsourceid><addsrcrecordid>eNqFkctKAzEUhoMoWi8LX0CyUXAxNicz0yTLMtYb3ha6E4ZMelIi05matFV3PoLP6JOY2oIrEQLJ4Xz85_CFkH1gJ8AY77pnEx9csDXSAaZEwjjk66QTeywRkPa2yHYIz4wB5CzbJFsAKpNZT3TI071vR00bps7Q4EaNs87oxiBtLR1Mvj4-i_4N7d-e0gv0seLdBme0naPHt4nHEFzbULc4cx3cHGnlUYcp_cnwu2TD6jrg3ureIY9ng4fiIrm-O78s-teJyWTKkmFuc1UpjhKltpUEazmHynCGykjRQ2lTxYFpi1xaoYwFJlSVMUBleZWmO-RomTvx7csMw7Qcu2CwrnWD7SyUAnIFOeT_giBTmadKRPB4CRrfhuDRlhPvxtq_l8DKhfMyOi9_nEf2YBU6q8Y4_CVXkiNwuAJ0MLq2Pspx4ZdLe_HP1GK77pJ7dTW-_z2xvLwqlqO_AdSpmRg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18385397</pqid></control><display><type>article</type><title>Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Spizzo, Gilbert ; Obrist, Peter ; Ensinger, Christian ; Theurl, Igor ; Dünser, Martina ; Ramoni, Angela ; Gunsilius, Eberhard ; Eibl, Günther ; Mikuz, Gregor ; Gastl, Günther</creator><creatorcontrib>Spizzo, Gilbert ; Obrist, Peter ; Ensinger, Christian ; Theurl, Igor ; Dünser, Martina ; Ramoni, Angela ; Gunsilius, Eberhard ; Eibl, Günther ; Mikuz, Gregor ; Gastl, Günther</creatorcontrib><description>To assess the frequency and prognostic impact of Ep‐CAM and Her‐2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow‐up of 10.8 years were enrolled in this retrospective study. Overexpression of Ep‐CAM and Her‐2/neu in tumor tissue samples was assessed by immunohistochemistry. Tumors presenting a Her‐2/neu 2+ staining were additionally analyzed by FISH to exclude false positive results. Ep‐CAM and Her‐2/neu overexpression was found in 35.6% and 19.5% of the tumor samples, respectively. Both Ep‐CAM and Her‐2/neu overexpression were predictive for poor disease‐free (DFS) and disease‐related overall survival (DROS). Concurrent Ep‐CAM and Her‐2/neu overexpression was present in 13.2% of tumor specimens and had an additive negative impact on DFS and DROS. This minority of patients had a median time to relapse of only 34 months, whereas the median time to relapse was not reached in the patient population without Her‐2/neu and Ep‐CAM overexpression. By multivariate analysis Ep‐CAM overexpression proved to be an indicator of poor prognosis, independent of tumor size, histologic grade, hormone receptor expression and Her‐2/neu overexpression. In conclusion, overexpression of Ep‐CAM and Her‐2/neu complement each other as predictors for poor prognosis in patients with invasive breast cancer. Determination of these tumor markers should help in assigning breast cancer patients to 1 of 3 distinct risk categories. © 2002 Wiley‐Liss, Inc.</description><identifier>ISSN: 0020-7136</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.10270</identifier><identifier>PMID: 11948467</identifier><identifier>CODEN: IJCNAW</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antigens, Neoplasm - genetics ; Antigens, Neoplasm - metabolism ; Biological and medical sciences ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; breast ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; cancer ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Lobular - metabolism ; Carcinoma, Lobular - pathology ; CD3 Complex - genetics ; CD3 Complex - metabolism ; Cell Adhesion Molecules - genetics ; Cell Adhesion Molecules - metabolism ; Disease-Free Survival ; Epithelial Cell Adhesion Molecule ; Ep‐CAM ; Female ; Gynecology. Andrology. Obstetrics ; Her‐2/neu ; Humans ; Immunoenzyme Techniques ; In Situ Hybridization, Fluorescence ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Staging ; Prognosis ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Retrospective Studies ; Tumors</subject><ispartof>International journal of cancer, 2002-04, Vol.98 (6), p.883-888</ispartof><rights>Copyright © 2002 Wiley‐Liss, Inc.</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2002 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4830-d5f59b92e8e8afb81ff221bc20e9c876e8f39210afe28f79cf1079b401e9f2b33</citedby><cites>FETCH-LOGICAL-c4830-d5f59b92e8e8afb81ff221bc20e9c876e8f39210afe28f79cf1079b401e9f2b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fijc.10270$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fijc.10270$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13609795$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11948467$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spizzo, Gilbert</creatorcontrib><creatorcontrib>Obrist, Peter</creatorcontrib><creatorcontrib>Ensinger, Christian</creatorcontrib><creatorcontrib>Theurl, Igor</creatorcontrib><creatorcontrib>Dünser, Martina</creatorcontrib><creatorcontrib>Ramoni, Angela</creatorcontrib><creatorcontrib>Gunsilius, Eberhard</creatorcontrib><creatorcontrib>Eibl, Günther</creatorcontrib><creatorcontrib>Mikuz, Gregor</creatorcontrib><creatorcontrib>Gastl, Günther</creatorcontrib><title>Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>To assess the frequency and prognostic impact of Ep‐CAM and Her‐2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow‐up of 10.8 years were enrolled in this retrospective study. Overexpression of Ep‐CAM and Her‐2/neu in tumor tissue samples was assessed by immunohistochemistry. Tumors presenting a Her‐2/neu 2+ staining were additionally analyzed by FISH to exclude false positive results. Ep‐CAM and Her‐2/neu overexpression was found in 35.6% and 19.5% of the tumor samples, respectively. Both Ep‐CAM and Her‐2/neu overexpression were predictive for poor disease‐free (DFS) and disease‐related overall survival (DROS). Concurrent Ep‐CAM and Her‐2/neu overexpression was present in 13.2% of tumor specimens and had an additive negative impact on DFS and DROS. This minority of patients had a median time to relapse of only 34 months, whereas the median time to relapse was not reached in the patient population without Her‐2/neu and Ep‐CAM overexpression. By multivariate analysis Ep‐CAM overexpression proved to be an indicator of poor prognosis, independent of tumor size, histologic grade, hormone receptor expression and Her‐2/neu overexpression. In conclusion, overexpression of Ep‐CAM and Her‐2/neu complement each other as predictors for poor prognosis in patients with invasive breast cancer. Determination of these tumor markers should help in assigning breast cancer patients to 1 of 3 distinct risk categories. © 2002 Wiley‐Liss, Inc.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antigens, Neoplasm - genetics</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>breast</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>cancer</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Lobular - metabolism</subject><subject>Carcinoma, Lobular - pathology</subject><subject>CD3 Complex - genetics</subject><subject>CD3 Complex - metabolism</subject><subject>Cell Adhesion Molecules - genetics</subject><subject>Cell Adhesion Molecules - metabolism</subject><subject>Disease-Free Survival</subject><subject>Epithelial Cell Adhesion Molecule</subject><subject>Ep‐CAM</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Her‐2/neu</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Retrospective Studies</subject><subject>Tumors</subject><issn>0020-7136</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkctKAzEUhoMoWi8LX0CyUXAxNicz0yTLMtYb3ha6E4ZMelIi05matFV3PoLP6JOY2oIrEQLJ4Xz85_CFkH1gJ8AY77pnEx9csDXSAaZEwjjk66QTeywRkPa2yHYIz4wB5CzbJFsAKpNZT3TI071vR00bps7Q4EaNs87oxiBtLR1Mvj4-i_4N7d-e0gv0seLdBme0naPHt4nHEFzbULc4cx3cHGnlUYcp_cnwu2TD6jrg3ureIY9ng4fiIrm-O78s-teJyWTKkmFuc1UpjhKltpUEazmHynCGykjRQ2lTxYFpi1xaoYwFJlSVMUBleZWmO-RomTvx7csMw7Qcu2CwrnWD7SyUAnIFOeT_giBTmadKRPB4CRrfhuDRlhPvxtq_l8DKhfMyOi9_nEf2YBU6q8Y4_CVXkiNwuAJ0MLq2Pspx4ZdLe_HP1GK77pJ7dTW-_z2xvLwqlqO_AdSpmRg</recordid><startdate>20020420</startdate><enddate>20020420</enddate><creator>Spizzo, Gilbert</creator><creator>Obrist, Peter</creator><creator>Ensinger, Christian</creator><creator>Theurl, Igor</creator><creator>Dünser, Martina</creator><creator>Ramoni, Angela</creator><creator>Gunsilius, Eberhard</creator><creator>Eibl, Günther</creator><creator>Mikuz, Gregor</creator><creator>Gastl, Günther</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20020420</creationdate><title>Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer</title><author>Spizzo, Gilbert ; Obrist, Peter ; Ensinger, Christian ; Theurl, Igor ; Dünser, Martina ; Ramoni, Angela ; Gunsilius, Eberhard ; Eibl, Günther ; Mikuz, Gregor ; Gastl, Günther</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4830-d5f59b92e8e8afb81ff221bc20e9c876e8f39210afe28f79cf1079b401e9f2b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antigens, Neoplasm - genetics</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>breast</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>cancer</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Lobular - metabolism</topic><topic>Carcinoma, Lobular - pathology</topic><topic>CD3 Complex - genetics</topic><topic>CD3 Complex - metabolism</topic><topic>Cell Adhesion Molecules - genetics</topic><topic>Cell Adhesion Molecules - metabolism</topic><topic>Disease-Free Survival</topic><topic>Epithelial Cell Adhesion Molecule</topic><topic>Ep‐CAM</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Her‐2/neu</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Retrospective Studies</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spizzo, Gilbert</creatorcontrib><creatorcontrib>Obrist, Peter</creatorcontrib><creatorcontrib>Ensinger, Christian</creatorcontrib><creatorcontrib>Theurl, Igor</creatorcontrib><creatorcontrib>Dünser, Martina</creatorcontrib><creatorcontrib>Ramoni, Angela</creatorcontrib><creatorcontrib>Gunsilius, Eberhard</creatorcontrib><creatorcontrib>Eibl, Günther</creatorcontrib><creatorcontrib>Mikuz, Gregor</creatorcontrib><creatorcontrib>Gastl, Günther</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Spizzo, Gilbert</au><au>Obrist, Peter</au><au>Ensinger, Christian</au><au>Theurl, Igor</au><au>Dünser, Martina</au><au>Ramoni, Angela</au><au>Gunsilius, Eberhard</au><au>Eibl, Günther</au><au>Mikuz, Gregor</au><au>Gastl, Günther</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2002-04-20</date><risdate>2002</risdate><volume>98</volume><issue>6</issue><spage>883</spage><epage>888</epage><pages>883-888</pages><issn>0020-7136</issn><eissn>1097-0215</eissn><coden>IJCNAW</coden><abstract>To assess the frequency and prognostic impact of Ep‐CAM and Her‐2/neu overexpression in patients with breast cancer and to determine its relationship with other prognostic markers, 205 breast cancer patients with a median follow‐up of 10.8 years were enrolled in this retrospective study. Overexpression of Ep‐CAM and Her‐2/neu in tumor tissue samples was assessed by immunohistochemistry. Tumors presenting a Her‐2/neu 2+ staining were additionally analyzed by FISH to exclude false positive results. Ep‐CAM and Her‐2/neu overexpression was found in 35.6% and 19.5% of the tumor samples, respectively. Both Ep‐CAM and Her‐2/neu overexpression were predictive for poor disease‐free (DFS) and disease‐related overall survival (DROS). Concurrent Ep‐CAM and Her‐2/neu overexpression was present in 13.2% of tumor specimens and had an additive negative impact on DFS and DROS. This minority of patients had a median time to relapse of only 34 months, whereas the median time to relapse was not reached in the patient population without Her‐2/neu and Ep‐CAM overexpression. By multivariate analysis Ep‐CAM overexpression proved to be an indicator of poor prognosis, independent of tumor size, histologic grade, hormone receptor expression and Her‐2/neu overexpression. In conclusion, overexpression of Ep‐CAM and Her‐2/neu complement each other as predictors for poor prognosis in patients with invasive breast cancer. Determination of these tumor markers should help in assigning breast cancer patients to 1 of 3 distinct risk categories. © 2002 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>11948467</pmid><doi>10.1002/ijc.10270</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2002-04, Vol.98 (6), p.883-888 |
| issn | 0020-7136 1097-0215 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71591515 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Antigens, Neoplasm - genetics Antigens, Neoplasm - metabolism Biological and medical sciences Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism breast Breast Neoplasms - metabolism Breast Neoplasms - pathology cancer Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Carcinoma, Lobular - metabolism Carcinoma, Lobular - pathology CD3 Complex - genetics CD3 Complex - metabolism Cell Adhesion Molecules - genetics Cell Adhesion Molecules - metabolism Disease-Free Survival Epithelial Cell Adhesion Molecule Ep‐CAM Female Gynecology. Andrology. Obstetrics Her‐2/neu Humans Immunoenzyme Techniques In Situ Hybridization, Fluorescence Mammary gland diseases Medical sciences Middle Aged Neoplasm Invasiveness Neoplasm Staging Prognosis Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Retrospective Studies Tumors |
| title | Prognostic significance of Ep‐CAM AND Her‐2/neu overexpression in invasive breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T04%3A26%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20significance%20of%20Ep%E2%80%90CAM%20AND%20Her%E2%80%902/neu%20overexpression%20in%20invasive%20breast%20cancer&rft.jtitle=International%20journal%20of%20cancer&rft.au=Spizzo,%20Gilbert&rft.date=2002-04-20&rft.volume=98&rft.issue=6&rft.spage=883&rft.epage=888&rft.pages=883-888&rft.issn=0020-7136&rft.eissn=1097-0215&rft.coden=IJCNAW&rft_id=info:doi/10.1002/ijc.10270&rft_dat=%3Cproquest_cross%3E71591515%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18385397&rft_id=info:pmid/11948467&rfr_iscdi=true |